Abstract
A patient with myelofibrosis with myeloid metaplasia displaying the V617F mutation of the JAK2 gene was given an allogeneic stem cell transplantation using a reduced-intensity conditioning regimen. The patient engrafted, and as he became a chimera, the expression of the V617F mutation of the JAK2 gene decreased progressively until its disappearance. Accordingly, the concept of "molecular remission" of the myelofibrosis with myeloid metaplasia could be entertained and added to the categories of response to treatment which have been recently described.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 400-402 |
| Number of pages | 3 |
| Journal | American Journal of Hematology |
| Volume | 82 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2007 |
Fingerprint
Keywords
- Bone marrow transplantation
- JAK2 V617F mutation
- Molecular remission
- Myelofibrosis with myeloid metaplasia
ASJC Scopus subject areas
- Hematology
Cite this
Clearance of the Janus Kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. / Ruiz-Argüelles, Guillermo J.; Garcés-Eisele, Javier; Reyes-Núñez, Virginia; Ruiz-Delgado, Guillermo J.; Rosillo, Carlos; Camoriano, John K.
In: American Journal of Hematology, Vol. 82, No. 5, 05.2007, p. 400-402.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clearance of the Janus Kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia
AU - Ruiz-Argüelles, Guillermo J.
AU - Garcés-Eisele, Javier
AU - Reyes-Núñez, Virginia
AU - Ruiz-Delgado, Guillermo J.
AU - Rosillo, Carlos
AU - Camoriano, John K
PY - 2007/5
Y1 - 2007/5
N2 - A patient with myelofibrosis with myeloid metaplasia displaying the V617F mutation of the JAK2 gene was given an allogeneic stem cell transplantation using a reduced-intensity conditioning regimen. The patient engrafted, and as he became a chimera, the expression of the V617F mutation of the JAK2 gene decreased progressively until its disappearance. Accordingly, the concept of "molecular remission" of the myelofibrosis with myeloid metaplasia could be entertained and added to the categories of response to treatment which have been recently described.
AB - A patient with myelofibrosis with myeloid metaplasia displaying the V617F mutation of the JAK2 gene was given an allogeneic stem cell transplantation using a reduced-intensity conditioning regimen. The patient engrafted, and as he became a chimera, the expression of the V617F mutation of the JAK2 gene decreased progressively until its disappearance. Accordingly, the concept of "molecular remission" of the myelofibrosis with myeloid metaplasia could be entertained and added to the categories of response to treatment which have been recently described.
KW - Bone marrow transplantation
KW - JAK2 V617F mutation
KW - Molecular remission
KW - Myelofibrosis with myeloid metaplasia
UR - http://www.scopus.com/inward/record.url?scp=34247487437&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247487437&partnerID=8YFLogxK
U2 - 10.1002/ajh.20832
DO - 10.1002/ajh.20832
M3 - Article
C2 - 17133423
AN - SCOPUS:34247487437
VL - 82
SP - 400
EP - 402
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 5
ER -